MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-01-2024
Bausch Health Companies Retained Earnings 2011-2025 | BHC
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.78 B | -9.19 B | -8.96 B | -8.01 B | -7.45 B | -5.66 B | -2.72 B | -5.13 B | -2.75 B | -2.36 B | -3.28 B | -2.37 B | -2.03 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.03 B | -9.78 B | -5.36 B |
Quarterly Retained Earnings Bausch Health Companies
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.83 B | -9.84 B | -9.78 B | -9.74 B | -9.36 B | -9.39 B | -9.19 B | -8.78 B | -9.18 B | -9.03 B | -8.96 B | -9.03 B | -9.22 B | -8.96 B | -8.01 B | -8.01 B | -8.01 B | -8.01 B | -7.45 B | -7.45 B | -7.45 B | -7.45 B | -5.66 B | -5.66 B | -5.66 B | -5.66 B | -2.72 B | -2.72 B | -2.72 B | -2.72 B | -5.13 B | -5.13 B | -5.13 B | -5.13 B | -2.75 B | -2.75 B | -2.75 B | -2.75 B | -2.4 B | -2.36 B | -2.36 B | -2.36 B | -3.28 B | -3.28 B | -3.28 B | -3.28 B | -2.37 B | -2.37 B | -2.37 B | -2.37 B | -2.03 B | -2.03 B | -2.03 B | -2.03 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.03 B | -9.84 B | -5.51 B |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 0.74 | -3.53 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.69 | -3.13 % | $ 182 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 3.06 | -6.57 % | $ 1.61 B | Canada |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 5.18 | -4.17 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 11.76 | 2.98 % | $ 602 M | USA |
 |
Evoke Pharma
EVOK
|
-123 M | $ 10.97 | 0.18 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | $ 21.39 | 0.14 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
-609 M | $ 7.17 | 1.85 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
-134 M | $ 46.47 | -1.25 % | $ 1.52 B | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 1.55 | -0.64 % | $ 27.1 M |  China |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 4.86 | 0.73 % | $ 640 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.82 | -5.36 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.03 | 19.57 % | $ 42.6 M | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 26.71 | 1.6 % | $ 1.24 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.88 | -5.09 % | $ 20.5 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 5.81 | -1.02 % | $ 237 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 3.45 | -3.96 % | $ 4.28 M | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.32 | 6.4 % | $ 130 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
-2.25 B | $ 12.85 | -2.17 % | $ 1.77 B | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | $ 0.11 | -2.7 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 2.02 | -8.68 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
Veru
VERU
|
-295 M | $ 2.43 | 0.41 % | $ 328 M | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
-182 M | $ 1.4 | 14.75 % | $ 6.04 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.64 | -1.21 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 11.41 | -6.09 % | $ 7.05 B | Canada |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 1.69 | -3.43 % | $ 17.6 M | USA |
 |
Zomedica Corp.
ZOM
|
-171 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 11.68 | 0.21 % | $ 14.2 B | USA |